Axitinib

Catalog No. A10103

Axitinib is a small molecule tyrosine kinase inhibitor,which inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117).
  • Youcef M. Rustum, .et al. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy, Int J Mol Sci, 2018, Nov; 19(11): 3378 PMID: 30380599
Catalog Num A10103
M. Wt 386.5
Formula C22H18N4OS
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 319460-85-0
Synonyms AG 013736
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
Axitinib is a small molecule tyrosine kinase inhibitor,which inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117).
Targets
Target Value
VEGFR1/FLT1IC50: 0.1nM
VEGFR2/Flk1IC50: 0.18nM
VEGFR2/KDRIC50: 0.2nM
VEGFR3IC50: 0.1nM-0.3nM
PDGFRβIC50: 1.6nM
KitIC50: 1.7nM
PDGFRαIC50: 5.0nM
CSF-1RIC50: 73nM
FLT3IC50: >1μM
In vitro (25°C) DMSO 35 mg/mL heating (90.56 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 25.87 mL 129.37 mL 258.73 mL
0.5 mM 5.17 mL 25.87 mL 51.75 mL
1 mM 2.59 mL 12.94 mL 25.87 mL
5 mM 0.52 mL 2.59 mL 5.17 mL

*The above data is based on the productmolecular weight 386.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.